The risks of handling cytotoxic drugs. I. Methods of testing exposure.

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Abstract Text:

Results of various biological and physical/chemical tests of the urines or blood of health-care personnel working with cytotoxic drugs are discussed. The outcomes of these tests are conflicting and inconclusive. The physical/chemical tests seem to be an alternative method. However, until now it has not been possible to establish the threshold concentration in urine or blood beneath which no effect has to be expected. Therefore, the interpretation of the concentration of cytotoxic drugs and/or the metabolites in the urine or blood is difficult. As long as one will not be able to provide conclusive data on the health hazards when working with cytotoxic drugs, protective measures have to be taken in order to lower the risk as much as possible.

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Publishing Authors By Initials

For similar investigative techniques: epidemiologic methods: statistics as topic: probability: risk research abstracts see: investigative techniques: epidemiologic methods: statistics as topic: probability: risk research

PUBMED ID PMID:

MEDLINE DATE:

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Journal Published:

PUBLICATION TYPE: Review

Journal: Pharmaceutisch weekblad. Scientific edition

VOLUME: 12

Page Numbers: 217-27

Journal Abbreviation:

ISSN: 0167-6555

DAY: 14

MONTH: Dec

YEAR: 1990

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Information

Number of References: 137

LANGUAGE: eng

NlmUniqueID: 7907992

The risks of handling cytotoxic drugs. I. Methods of testing exposure. Keywords Mesh Terms:

KEYWORDS: Risk

MESH TERMS: chemically induced

Chemical & Substance for Abstract: The risks of handling cytotoxic drugs. I. Methods of testing exposure. Information

Substance Name: Antineoplastic Agents

Registry Number: 0

Grant and Affiliation Information for The risks of handling cytotoxic drugs. I. Methods of testing exposure.

AFFILIATION: Pharmaceutical Laboratory, Utrecht University, The Netherlands.

Country: NETHERLANDS

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Pharm Weekbl Sci

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

The risks of handling cytotoxic drugs I Methods of testing exposure Related Publications

• A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
• Amyloid Beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
• Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
• Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
• Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
• Didanosine, a new antiretroviral drug. A review.
• Dideoxynucleoside therapy for HIV infection.
• Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
• Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
• Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin(R) g
• Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
• Home-based chemotherapy confronts pharmacists with stability and compatibility problems.
• Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
• Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
• Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH(4) with biomarker potential in human plasma and serum.
• New cytotoxic drugs and targets in oncology.
• Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
• Platinum antitumour agents: a review of (bio)analysis.
• Prescription error resulting in valproic acid intoxication.
• Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
• Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
• Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
• Serum Amyloid Beta Peptides in Patients with Dementia and Age-Matched Non-Demented Controls as Detected by Surface-Enhanced Laser Desorption Ionisation-Time of Flight Mass Spectrometry (SELDI-TOF MS).
• The risks of handling cytotoxic drugs. I. Methods of testing exposure.
• The risks of handling cytotoxic drugs. II. Recommendations for working with cytotoxic drugs.